Bringing Biotech To The Barnyard

Human genomics and genetic analysis gets a great deal of attention from investors and journalists. That attention is well-deserved, as a single cancer drug can be worth as much as $100,000 per year per patient. Clearly, that provides ample incentive for major drug companies to invest heavily in genomic equipment in the hopes of developing more effective drugs.


By no means is it just a pharmaceutical opportunity, either. Myriad Genetics (Nasdaq:MYGN) has built an attractive niche in gene-based cancer diagnostics, and larger players like Abbott Labs are also delving deep into molecular and genome-based diagnostics.

But why should people have all the fun? The cattle industry alone is worth about $80 billion a year in the United States, and there is clearly substantial money to be made in getting the best out of every Bessie and Wilbur in the feed lots.


You can read the full piece at: 
http://stocks.investopedia.com/stock-analysis/2010/Bringing-Biotech-To-The-Barnyard-MYGN-AFFX-ILMN-SQNM-TSN-WFMI-LMNX-NEOG0617.aspx

Monsanto - A Non-Commodity Commodity Play (MON, DD)

Here's the latest I've written on Monsanto for Investopedia.
http://community.investopedia.com/news/IA/2008/Monsanto---A-Non-Commodity-Commodity-Play-MON-DD1015.aspx

I've long loved this company and lamented the valuation. Boy howdy is this a volatile one!

Cheers
ss